NOK 3.47
(-8.44%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -1.79 NOK | -27.86% |
2022 | -1.40 NOK | 20.0% |
2021 | -1.75 NOK | -88.17% |
2020 | -0.93 NOK | -481.25% |
2019 | -0.16 NOK | -127.27% |
2018 | -0.07 NOK | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q2 | -0.47 NOK | 0.0% |
2024 Q1 | -0.47 NOK | 4.08% |
2023 Q4 | -0.49 NOK | 0.0% |
2023 FY | - NOK | -27.86% |
2023 Q1 | - NOK | 100.0% |
2023 Q3 | -0.49 NOK | 0.0% |
2023 Q2 | - NOK | 0.0% |
2022 Q4 | -0.39 NOK | 0.0% |
2022 FY | - NOK | 20.0% |
2021 FY | - NOK | -88.17% |
2020 FY | - NOK | -481.25% |
2019 FY | - NOK | -127.27% |
2018 FY | - NOK | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Aqua Bio Technology ASA | -0.99 NOK | -80.808% |
ArcticZymes Technologies ASA | 0.38 NOK | 571.053% |
BerGenBio ASA | -13.30 NOK | 86.541% |
Hofseth BioCare ASA | -0.27 NOK | -562.963% |
PCI Biotech Holding ASA | -0.54 NOK | -231.481% |
Thor Medical ASA | -0.03 NOK | -5528.931% |
Ultimovacs ASA | -5.50 NOK | 67.455% |